Physician profile
Michael Alan Boyd
NPI 1740270115
$8,153.93
in general payments reported to CMS, 2019-2025
36 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $782 · 2021: $807 · 2022: $925 · 2023: $1,543 · 2024: $1,732 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,699 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,699.48 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,457.09 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $877.48 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $757.88 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $614.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $612.69 | 2022-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $430.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.55 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Lundbeck LLC | $327.04 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $296.61 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $280.37 | 2020-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.14 | 2020-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $210.32 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $192.50 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $186.83 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $151.98 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $149.73 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $143.05 | 2019-2022 | |
| Allergan, INC. | $124.66 | 2020 | |
| Janssen Pharmaceuticals, INC | $109.05 | 2019-2021 | |
| Glaxosmithkline, LLC. | $78.76 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.98 | 2022 | |
| Exact Sciences Corporation | $59.41 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $51.07 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $49.94 | 2021 | |
| Nabriva Therapeutics, Plc | $43.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.95 | 2019-2022 | |
| Eisai INC. | $31.00 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $23.54 | 2020-2022 | |
| Dexcom, INC. | $20.70 | 2025 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $20.61 | 2025 | Collagenase Santyl |
| E.R. Squibb & Sons, L.L.C. | $18.71 | 2023 | |
| Kyowa Kirin, INC. | $17.43 | 2019 | |
| Amgen INC. | $15.90 | 2020 | |
| Abiomed | $14.47 | 2024 | Impella |
| Amarin Pharma, INC. | $13.09 | 2019 | |
| Shire North American Group INC | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.